Is Stoke Therapeutics, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Stoke Therapeutics, Inc. has moved from fair to expensive, indicating that the stock is overvalued. The company exhibits a P/E ratio of 12, a Price to Book Value of 1.74, and an EV to EBITDA ratio of 5.94, which are relatively low compared to its peers. For instance, CorMedix, Inc. has a P/E of 18.60, while Taysha Gene Therapies, Inc. shows a negative P/E, highlighting the varying valuations within the sector.
Despite the company's strong recent performance, with a year-to-date return of 203.99% compared to the S&P 500's 13.30%, the overall valuation metrics suggest that Stoke Therapeutics is not a bargain at its current price. The significant disparity in valuation ratios compared to peers reinforces the conclusion that the stock is overvalued.